DC-CIK细胞联合手术治疗原发性肝癌的临床研究

DC-CIK cells combined with surgical treatment for hepatocellular carcinoma

摘要:

目的：评价树突状细胞（Dendritic cells，DC）-细胞因子激活的杀伤细胞（Cytokine induced killer，CIK）即DC-CIK细胞联合手术治疗原发性肝癌的临床疗效。方法：将67例原发性肝癌患者随机分为治疗组和对照组，治疗组34例，行肝癌切除术，术后给予DC-CIK细胞治疗。对照组33例，行肝癌切除术。治疗结束后比较2组的免疫功能、生活质量、生存率、肿瘤复发率及不良反应。结果：治疗组DC-CIK细胞治疗后CD3+、CD4+、CD16+CD56+和CD4+/CD8+ 比值明显上升，CD8+ 效应细胞比例下降，与治疗前比较差异有统计学意义（P<0.05）。与对照组比较，治疗组治疗后CD3+、CD4+、CD16+CD56+和CD4+/CD8+ 比值显著上升，CD8+效应细胞比例显著下降，差异有统计学意义（P<0.05）。治疗组有61.8%的患者生活质量得到改善，明显高于对照组的36.4%（P<0.05）。治疗组的1年生存率为91.2%，对照组为81.8%，治疗组的1年复发率为8.8%，对照组为15.2%，两组比较差异无统计学意义（P >0.05）。自体DC-CIK细胞治疗常见的副反应为发热、寒颤，对症处理后均可缓解。结论：DC-CIK细胞联合手术治疗原发性肝癌安全有效，对提高肝癌患者的免疫功能，改善患者生活质量，提高治疗效果具有重要作用。

Abstract:

Objective：To evaluate the clinical efficacy of dendritic cells-cytokine induced killer（DC-CIK） cells combined with surgi－cal treatment for hepatocellular carcinoma（HCC）. Methods：Totally 67 patients with HCC were randomly divided into treatment group （n=34） and control group（n=33）. The patients in control group were received hepatectomy while those in treatment group were given hepatectomy combined with DC-CIK cell treatment. The immune function，quality of life，tumor recurrence rate and adverse reactions were analyzed postoperatively. Results：In treatment group，the proportion of CD3+，CD4+，CD16+CD56+ and the ratio of CD4+ against CD8+ were increased and the proportion of CD8+ effect cells was decreased significantly after DC-CIK cell treatment compared with those before DC-CIK cell treatment，with statistical differences（P<0.05）. After treatment，the proportion of CD3+，CD4+，CD16+CD56+ and the ratio of CD4+ against CD8+ were increased and the proportion of CD8+ effect cells was decreased significantly in treatment group compared with those in control group，with statistical differences（P<0.05）. Quality of life of 61.8% patients in treatment group was improved，significantly higher than that of 36.4% in control group（P<0.05）. The 1-year survival rate and 1-year recurrence rate in treatment group and control group were 91.2% vs. 81.8% and 8.8% vs. 15.2% respectively，with no significant statistical difference between two groups（P >0.05）. The side effects of DC-CIK cells treatment were fever，chills and could be alleviated after symptomatic treatment. Conclusions：DC-CIK cells combined with surgical treatment for patients with hepatocellular carcinoma is safe and effec－tive and it plays an important role in improving immune function and quality of life of HCC patients.